These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 26260983)
1. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Savic RM; Ruslami R; Hibma JE; Hesseling A; Ramachandran G; Ganiem AR; Swaminathan S; McIlleron H; Gupta A; Thakur K; van Crevel R; Aarnoutse R; Dooley KE Clin Pharmacol Ther; 2015 Dec; 98(6):622-9. PubMed ID: 26260983 [TBL] [Abstract][Full Text] [Related]
2. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Heemskerk D; Day J; Chau TT; Dung NH; Yen NT; Bang ND; Merson L; Olliaro P; Pouplin T; Caws M; Wolbers M; Farrar J Trials; 2011 Feb; 12():25. PubMed ID: 21288325 [TBL] [Abstract][Full Text] [Related]
3. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. Pouplin T; Bang ND; Toi PV; Phuong PN; Dung NH; Duong TN; Caws M; Thwaites GE; Tarning J; Day JN BMC Infect Dis; 2016 Apr; 16():144. PubMed ID: 27039088 [TBL] [Abstract][Full Text] [Related]
4. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Thwaites GE; Bhavnani SM; Chau TT; Hammel JP; Török ME; Van Wart SA; Mai PP; Reynolds DK; Caws M; Dung NT; Hien TT; Kulawy R; Farrar J; Ambrose PG Antimicrob Agents Chemother; 2011 Jul; 55(7):3244-53. PubMed ID: 21502621 [TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis. Panjasawatwong N; Wattanakul T; Hoglund RM; Bang ND; Pouplin T; Nosoongnoen W; Ngo VN; Day JN; Tarning J Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139294 [TBL] [Abstract][Full Text] [Related]
7. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis. Dian S; Yunivita V; Ganiem AR; Pramaesya T; Chaidir L; Wahyudi K; Achmad TH; Colbers A; Te Brake L; van Crevel R; Ruslami R; Aarnoutse R Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224533 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327 [TBL] [Abstract][Full Text] [Related]
9. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Donald PR Tuberculosis (Edinb); 2010 Sep; 90(5):279-92. PubMed ID: 20709598 [TBL] [Abstract][Full Text] [Related]
11. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Ellard GA; Humphries MJ; Allen BW Am Rev Respir Dis; 1993 Sep; 148(3):650-5. PubMed ID: 8368635 [TBL] [Abstract][Full Text] [Related]
13. Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. Mezochow A; Thakur KT; Zentner I; Subbian S; Kagan L; Vinnard C Int J Infect Dis; 2019 Jul; 84():15-21. PubMed ID: 31051278 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of additional levofloxacin in tuberculous meningitis: A randomized controlled pilot study. Kalita J; Bhoi SK; Betai S; Misra UK Tuberculosis (Edinb); 2016 May; 98():1-6. PubMed ID: 27156611 [TBL] [Abstract][Full Text] [Related]
15. Preclinical models to optimize treatment of tuberculous meningitis - A systematic review. Litjens CHC; Aarnoutse RE; Te Brake LHM Tuberculosis (Edinb); 2020 May; 122():101924. PubMed ID: 32501258 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Te Brake L; Dian S; Ganiem AR; Ruesen C; Burger D; Donders R; Ruslami R; van Crevel R; Aarnoutse R Int J Antimicrob Agents; 2015 May; 45(5):496-503. PubMed ID: 25703312 [TBL] [Abstract][Full Text] [Related]
17. Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Paradkar MS; Devaleenal D B; Mvalo T; Arenivas A; Thakur KT; Wolf L; Nimkar S; Inamdar S; Giridharan P; Selladurai E; Kinikar A; Valvi C; Khwaja S; Gadama D; Balaji S; Yadav Kattagoni K; Venkatesan M; Savic R; Swaminathan S; Gupta A; Gupte N; Mave V; Dooley KE; Clin Infect Dis; 2022 Oct; 75(9):1594-1601. PubMed ID: 35291004 [TBL] [Abstract][Full Text] [Related]
18. Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis. Kaojarern S; Supmonchai K; Phuapradit P; Mokkhavesa C; Krittiyanunt S Clin Pharmacol Ther; 1991 Jan; 49(1):6-12. PubMed ID: 1988241 [TBL] [Abstract][Full Text] [Related]
19. Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. Guiastrennec B; Ramachandran G; Karlsson MO; Kumar AKH; Bhavani PK; Gangadevi NP; Swaminathan S; Gupta A; Dooley KE; Savic RM Clin Pharmacol Ther; 2018 Oct; 104(4):733-741. PubMed ID: 29247506 [TBL] [Abstract][Full Text] [Related]
20. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Jeena PM; Bishai WR; Pasipanodya JG; Gumbo T Antimicrob Agents Chemother; 2011 Feb; 55(2):539-45. PubMed ID: 21098246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]